2 results
Approved WMOPending
1. The primary aim of the study is to investigate whether periodontal treatment results in a decrease of plasma biomarkers that are related to cardiovascular diseases (CVD) and metabolic syndrome (MS) and what is the effect of the treatment on the…
Approved WMORecruiting
The anti-TIM-3 monoclonal antibody MBG453 is a novel immunotherapeutic agent with promising activity seen in AML and MDS. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with…